İrem İYİGÜNDOĞDU, İsmet ÇOK, Mesut YILDIRIM

COVID-19 and the role of e-cigarette use: An evidence-based review

While the world is grappling with one of the biggest pandemics in history, the role that personal preferences or lifestyles can play in the development of this pandemic should not be overlooked. One of these preferences is the use of electronic cigarettes (e-cigarettes). COVID-19 is a disease that primarily attacks the lungs. Thus, factors that cause pre-existing lung disease such as e-cigarette use may increase the risk for critical complications from COVID-19. Promoted as an alternative to conventional cigarettes, e-cigarettes induce inflammation of human airways and possibly increase susceptibility toward pneumonia because of an increase of pneumococcal adherence to airway cells. Lung damage caused by flavorings contained in e-cigarettes can increase health risks, especially from COVID-19. When compared to nonsmokers, e-cigarette users had a five times increased risk while dual users with tobacco had a seven times increased risk of COVID-19 infection. Recent research supports that many medical consequences such as lung inflammation and increased susceptibility to pulmonary viral and bacterial infections in smokers and people with COVID-19 disease may also develop due to e-cigarette use. The aim of this article is to investigate whether there is a role for e-cigarette use in the development of respiratory diseases caused by the COVID-19 virus. With the help of our experience of working on e-cigarettes for many years and various scientific databases (PubMed, Scopus, etc.), the health risks experienced by people who both use e-cigarettes and have a COVID-19 virus infection, and the role of respiratory system symptoms, in particular, were investigated.

PDF

___

[1] Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, Hayati Z, Wagner AL, Mudatsir M. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020; 13: 667-673.
[2] Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front. Med. 2020; 14: 126-135.
[3] Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020; 18: 20.
[4] Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis. medRxiv [Preprint] 2020.
[5] Egbe CO, Ngobese SP. COVID-19 lockdown and the tobacco product ban in South Africa. Tob Induc Dis. 2020; 18: 39.
[6] Göney G, Çok İ, Tamer U, Burgaz S, Şengezer T. Urinary cotinine levels of electronic cigarette (e-cigarette) users. Toxicol Mech Methods. 2016; 26(6): 441-445.
[7] Han S, Chen H, Zhang X, Liu T, Fu Y. Levels of selected groups of compounds in refill solutions for electronic cigarettes. Nicotine Tob Res. 2016; 18(5): 708-714.
[8] Beauval N, Antherieu S, Soyez M, Gengler N, Grova N, Howsam M, Hardy EM, Fischer M, Appenzeller BMR, Goossens JF, Allorge D, Garcon G, Lo-Guidice JM, Garat A. Chemical evaluation of electronic cigarettes: multicomponent analysis of liquid refills and their corresponding aerosols. J Anal Toxicol. 2017; 41: 670-678.
[9] Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, RosikDulewska C, Havel C, Jacob P 3rd, Benowitz N. Levels of selected carcinogens and toxicans in vapour from electronic cigarettes. Tob Control. 2014; 23(2): 133-139.
[10] Olmedo P, Goessler W, Tanda S, Grau-Perez M, Jarmul S, Aherrera A, Chen R, Hilpert M, Cohen JE, Navas-Acien A, Rule AM. Metal concentrations in e-cigarette liquid and aerosol samples: the contribution of metallic coils. Environ Health Perspect. 2018; 126(2): 027010.
[11] Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, You R, Hong MJ, Baghaei N, Song LZ, Porter P, Putluri N, Salas R, Gilbert BE, Levental I, Campen MJ, Corry DB, Kheradmand F. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest. 2019; 129(10): 4290-4304.
[12] Wang TW, Gentzke A, Sharapova S, Cullen KA, Ambrose BK, Jamal A. Tobacco product use among middle and high school students—United States, 2011-2017. MMWR Morb Mortal Wkly Rep. 2018; 67(22): 629-633.
[13] Tackett AP, Keller-Hamilton B, Smith CE, Hébert ET, Metcalf JP, Queimado L, Stevens EM, Wallace SW, McQuaid EL, Wagener TL. Evaluation of respiratory symptoms among youth e-cigarette users. JAMA Netw Open. 2020; 3(10): e2020671.
[14] McCauley L, Markin C, Hosmer D. An unexpected consequence of electronic cigarette use. Chest 2012; 141(4): 1110– 1113.
[15] McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, Samet J, Leventhal A, Berhane K. Electronic cigarette use and respiratory symptoms in adolescents. Am J Respir Crit Care Med. 2017; 195(8): 1043-1049.
[16] Wang MP, Ho SY, Leung LT, Lam TH. Electronic cigarette use and respiratory symptoms in Chinese adolescents in Hong Kong. JAMA Pediatr. 2016; 170(1): 89-91.
[17] Cho JH, Paik SY. Association between electronic cigarette use and asthma among high school students in South Korea. PLoS One 2016; 11(3): e0151022.
[18] Wills TA, Pagano I, Williams RJ, Tam EK. E-cigarette use and respiratory disorder in an adult sample. Drug Alcohol Depend. 2019; 194: 363-370.
[19] Hedman L, Backman H, Stridsman C, Bosson JA, Lundback M, Lindberg A, Rönmark E, Ekerljung L. Association of electronic cigarette use with smoking habits, demographic factors, and respiratory symptoms. JAMA Netw Open 2018; 1(3): e180789.
[20] Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, Navon L, Hoots B, Salvatore PP, Elderbrook M, Haupt T, Kanne J, Patel MT, Saathoff-Huber L, King BA, Schier JG, Mikosz CA, Meiman J. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin - final report. N Engl J Med. 2020; 382(10): 903–916.
[21] Schweitzer RJ, Wills TA, Tam E, Pagano I, Choi K. E-cigarette use and asthma in a multiethnic sample of adolescents. Prev Med. 2017; 105: 226-231.
[22] Reid KM, Forrest JR, Porter L. Tobacco product use among youths with and without lifetime asthma - Florida, 2016. MMWR Morb Mortal Wkly Rep. 2018; 67(21): 599-601.
[23] Wang JB, Olgin JE, Nah G, Vittinghoff E, Cataldo JK, Pletcher MJ, Marcus GM. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. PLoS One. 2018; 13(7): e0198681.
[24] Ghosh A, Coakley RD, Ghio AJ, Muhlebach MS, Esther CR Jr, Alexis NE, Tarran R. Chronic e-cigarette use increases neutrophil elastase and matrix metalloprotease levels in the lung. Am J Respir Crit Care Med. 2019; 200(11): 1392– 1401.
[25] Miyashita L, Foley G. E-cigarettes and respiratory health: the latest evidence. J Physiol. 2020; 598(22): 5027-5038.
[26] Temas D, Meyer A. E-cigarette- and vaping- related lung injury (EVALI) at a regional hospital system in South Carolina. Case Rep Pulmonol. 2020; 2020: 5370606.
[27] Lee AC, Chakladar J, Li WT, Chen C, Chang EY, Wang-Rodriguez J, Ongkeko WM. Tobacco, but not nicotine and flavor-less electronic cigarettes, induces ACE2 and immune dysregulation. Int J Mol Sci. 2020; 21(15): 5513.
[28] Rowell TR, Tarran R. Will chronic e –cigarette use cause lung disease? Am J Physiol Lung Cell Mol Physiol. 2015; 309(12): L1398-1409.
[29] World Health Organization (WHO). Smoking and COVID-19. https://www.who.int/newsroom/commentaries/detail/smoking-and-covid-19 (accessed March 01, 2021).
[30] Gaiha SM, Cheng J, Halpern-Felsher B. Association between youth smoking, electronic cigarette use, and COVID-19. J Adolesc Health. 2020; 67(4): 519-523.
[31] Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018; 18(1): 574.
[32] Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004; 164(20): 2206–2216.
[33] Pino LE, Trianna I, Perez C, Piotrostanalzki A, Ruiz- Patino A, Lopes G, Cardona AF. Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers. Clin Transl Oncol. 2021; 23(1): 5-9.
[34] Reidel B, Radicioni G, Clapp PW, Ford AA, Abdelwahab S, Rebuli ME, Haridass P, Alexis NE, Jaspers I, Kesimer M. E-Cigarette use causes a unique innate immune response in the lung, involving increased neutrophilic activation and altered mucin secretion. Am J Respir Crit Care Med. 2018; 197(4): 492–501.
[35] Tsai M, Song MA, McAndrew C, Brasky TM, Freudenheim JL, Mathe E, McElroy J, Reisinger SA, Shields PG, Wewers MD. Electronic versus combustible cigarette effects on inflammasome component release into human lung. Am J Respir Crit Care Med. 2019; 199(7): 922–925.
[36] Wang Q, Sundar IK, Li D, Lucas JH, Muthumalage T, McDonough SR, Rahman I. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR α7 receptor: role of nAChR α7 in SARS –CoV-2 COVID-19 ACE2 receptor regulation. Respir Res. 2020; 21(1): 154.
[37] Kamada T, Yamashita Y, Tomioka H. Acute eosinophilic pneumonia following heat-not-burn cigarette smoking. Respirol Case Rep. 2016; 4(6): e00190.
[38] Itoh M, Aoshiba K, Herai Y, Nakamura H, Takemura T. Lung injury associated with electronic cigarettes inhalation diagnosed by transbronchial lung biopsy. Respirol Case Rep. 2017; 6(1): e00282.
[39] Centers for Disease Control and Prevention (CDC) Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lungdisease.html#latest-information (accessed April 01, 2021).
[40] Belok SH, Parikh R, Bernardo J, Kathuria H. E-cigarette, or vaping, product use-associated lung injury: a review. Pneumonia (Nathan). 2020; 12: 12.
[41] Brown A, Balk SJ. E-cigarettes and other electronic nicotine delivery systems (ENDS). Curr Probl Pediatr Adolesc Health Care. 2020; 50(2): 100761.
[42] Galo J, Celli D, Gross D, Holt G, Campos M. A presentation of e-cigarette vaping associated lung injury (EVALI) caused by THC-Containing electronic smoking device. Respir Med Case Rep. 2020; 31: 101154.
[43] Ansari-Gilani K, Petraszko AM, Gilkeson RC. COVID-19 pneumonia versus EVALI, distinguishing the overlapping CT features in the COVID-19 era. Heart Lung. 2020; 49(6): 885-886.
[44] Patel VN, Rouse M, Brown C, Pandya S. Ground glass opacities observed in a 26-year-old coronavirus disease 2019 (COVID-19) rule-out patient with a history of vape use. Cureus. 2020; 12(9): e10302.
[45] Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B, Yang W. Prognostic value of C-reactive protein in patients with Coronavirus 2019. Clin Infect Dis. 2020; 71(16): 2174-2179.
[46] Kalininskiy A, Bach CT, Nacca NE, Gingsberg G, Marraffa J, Navarette KA, McGraw MD, Croft DP. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med. 2019; 7(12): 1017–1026.
[47] Sussman RA, Golberstein E, Polosa R. Aerial transmission of the SARS-CoV-2 virus through environmental ecigarette aerosols: implications for public policies. Int J Environ Res Public Health. 2021; 18(4): 1437.
[48] Hopkins DB, Al-Hamdani M. Young Canadian e-cigarette users and the COVID-19 pandemic: examining vaping behaviors by pandemic onset and gender. Front Public Health. 2021; 8: 620748.
[49] Soule EK, Mayne S, Snipes W, Guy MC, Breland A, Fagan P. Impacts of COVID-19 on electronic cigarette purchasing, use and related behaviors. Int J Environ Res Public Health. 2020; 17(18): 6762.
[50] Andreu-Mondon M, Barrio-Gimenez P, Mondon-Vehils S. COVID-19 and restrictions on tobacco use. Med Clin (Barc). 2021; 156(2): 93 ( article in English and in Spanish).